ABCG2 and breast cancer: For instance, Safaei et al. [40] developed a transmembrane peptide (TAT)-conjugated liposomal nanocarrier for the delivery of trastuzumab and siRNA targeting breast cancer resistance protein (BCRP) to overcome multidrug resistance in breast cancer.